RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Northwest Biotherapeutics P/E 2024

Northwest Biotherapeutics P/E

-10.61

Northwest Biotherapeutics Dividend yield

Ticker

NWBO

ISIN

US66737P6007

WKN

A1J5EY

As of May 21, 2024, Northwest Biotherapeutics's P/E ratio was -10.61, a 61.25% change from the -6.58 P/E ratio recorded in the previous year.

The Northwest Biotherapeutics P/E history

Northwest Biotherapeutics Aktienanalyse

What does Northwest Biotherapeutics do?

Northwest Biotherapeutics Inc is a biotherapy company specializing in immunotherapy and targeted therapy for the treatment of cancer. The company was founded in 1996 and is based in Bethesda, Maryland, USA. The company started as a startup founded by Dr. Alton Boynton, a former Assistant Professor at Georgetown University School of Medicine and an experienced cancer researcher. Recognizing the potential of immunotherapy for the treatment of cancer, Boynton founded the company with the goal of developing new immunotherapy products. In the early 2000s, the company made significant progress. It received FDA approval for a Phase I clinical trial of its first immunotherapy product, DCVax-L, for the treatment of glioblastoma, a type of brain tumor. The company also expanded its presence in Europe and established a subsidiary in the UK. In 2010, the company conducted a successful Phase II trial of DCVax-L and received Fast Track designation from the US Food and Drug Administration (FDA). In 2012, the company was listed on the NASDAQ Capital Market (NASDAQ: NWBO). The business model of Northwest Biotherapeutics Inc is based on the development and commercialization of immunotherapy products for the treatment of cancer. It focuses on developing personalized immunotherapy tailored to the biological characteristics of individual patients. This approach allows the company to develop targeted products that aim at specific types of cancer. Northwest Biotherapeutics Inc has a partnership with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany to support its product development. The partnership enables the use of state-of-the-art technologies for the manufacturing and characterization of cell therapies and allows the company to improve its immunotherapy products. The main product of Northwest Biotherapeutics Inc is DCVax-L, a personalized immunotherapy for the treatment of glioblastoma. DCVax-L is a cell-based therapy that uses the patient's dendritic cells to activate the immune system and fight against cancer. DCVax-L has been studied in Phase I and Phase II clinical trials in both the US and Europe. The company is also developing other immunotherapy products, including DCVax-Direct, a therapy for direct injection of dendritic cells into tumors. The company is also working on the development of DCVax-Prostate, a personalized immunotherapy for the treatment of prostate cancer. In addition to its research and development work, the company collaborates closely with patient organizations, scientists, and physicians to raise awareness of immunotherapy and personalized medicine. It also works with regulatory authorities and healthcare systems to facilitate access to its immunotherapy products. In conclusion, Northwest Biotherapeutics Inc is an innovative biotherapy company specializing in the development of personalized immunotherapy products for the treatment of cancer. With its focus on targeted therapy, the company has the potential to advance the field of immunotherapy and improve the quality of life for cancer patients. Northwest Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Northwest Biotherapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Northwest Biotherapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Northwest Biotherapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Northwest Biotherapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Northwest Biotherapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Northwest Biotherapeutics Stock

What is the price-to-earnings ratio of Northwest Biotherapeutics?

The price-earnings ratio of Northwest Biotherapeutics is currently -10.61.

How has the price-earnings ratio of Northwest Biotherapeutics changed compared to last year?

The price-to-earnings ratio of Northwest Biotherapeutics has increased by 61.25% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Northwest Biotherapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Northwest Biotherapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Northwest Biotherapeutics affect the company?

An increase in the price-earnings ratio of Northwest Biotherapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Northwest Biotherapeutics affect the company?

A decrease in the price-earnings ratio of Northwest Biotherapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Northwest Biotherapeutics?

Some factors that influence the price-earnings ratio of Northwest Biotherapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Northwest Biotherapeutics pay?

Over the past 12 months, Northwest Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Northwest Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Northwest Biotherapeutics?

The current dividend yield of Northwest Biotherapeutics is .

When does Northwest Biotherapeutics pay dividends?

Northwest Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Northwest Biotherapeutics?

Northwest Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of Northwest Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Northwest Biotherapeutics located?

Northwest Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Northwest Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Northwest Biotherapeutics from 5/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/21/2024.

When did Northwest Biotherapeutics pay the last dividend?

The last dividend was paid out on 5/21/2024.

What was the dividend of Northwest Biotherapeutics in the year 2023?

In the year 2023, Northwest Biotherapeutics distributed 0 USD as dividends.

In which currency does Northwest Biotherapeutics pay out the dividend?

The dividends of Northwest Biotherapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Northwest Biotherapeutics

Our stock analysis for Northwest Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Northwest Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.